Non-Hodgkin Lymphoma Articles

Navigating the Toxicities of Novel-Novel Combinations in Lymphoma
Combinations of novel drugs in lymphomas have the potential to overcome resistance to therapy but come with sometimes unexpected adverse events that demand careful monitoring.
CAR T-cell Therapies Offer Hope for DLBCL
Chimeric antigen receptor T-cell therapies have quickly moved from early phase clinical trials to FDA approval for diffuse large B-cell lymphoma, with research now exploring ways to shift these agents earlier in the treatment paradigm.
Frontline Ibrutinib Plus R-CHOP Misses Primary Endpoint in Phase III DLBCL Trial
Combining ibrutinib with standard R-CHOP did not improve event-free survival versus R-CHOP alone in the first-line setting for patients with diffuse large B-cell lymphoma. 
PFS Valid Surrogate Endpoint for Overall Survival in Frontline DLBCL
Progression-free survival appears to be a surrogate endpoint for overall survival in patients undergoing firstline treatment for diffuse large B-cell lymphoma, according to results from a large pooled analysis.
Pixantrone Falls Short in Phase III B-Cell NHL Trial
Combining pixantrone (Pixuvri) with rituximab (Rituxan) failed to improve progression-free survival compared with gemcitabine plus rituximab in patients with aggressive B-cell non-Hodgkin lymphoma. 
Axicabtagene Ciloleucel Approaches EU Approval for DLBCL, PMBCL
The European Medicines Agency’s CHMP has recommended approval of axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma.
Tisagenlecleucel Nears European Approval for DLBCL, ALL
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of tisagenlecleucel for the treatment of either adult patients with diffuse large B-cell lymphoma that is relapsed or refractory after 2 or more lines of systemic therapy, or patients up to 25 years of age with B-cell acute lymphoblastic leukemia that is refractory, in relapse posttransplant, or in second or later relapse.
FDA Grants Ibrutinib/Rituximab Priority Review for Waldenstrom Macroglobulinemia
The FDA has granted a priority review to a supplemental new drug application for ibrutinib for use in combination with rituximab as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia.
Expert Discusses Venetoclax Potential in MCL
Toby Eyre, MBChB, MRCP, discusses the results of the phase I study with venetoclax in patients with poor-risk relapsed/refractory mantle cell lymphoma.
Novel Targeted Antibody-Drug Conjugates in Non-Hodgkin Lymphoma
Antibody-drug conjugates represent a targeted class of agents with an improved therapeutic index over traditional chemotherapy in the treatment of non-Hodgkin lymphoma.
Publication Bottom Border
Border Publication